Date: April 20, 2010
CRF Investigator Connie Trimble
Cervical cancer is caused by human papillomavirus (HPV) infection.
Precancerous lesions occur years before cancer and are easily detectable
through pap smears. Still cancer rates among women in Baltimore City and
Maryland’s Eastern Shore are three times the national average.
Researchers work to develop a vaccine that causes immune cells to recognize
and attack HPV and clear it out. Without the virus, the cancer cannot survive.
With one shot in each arm, a 44-year-old woman, becomes the first patient to
receive Johns Hopkins-developed therapeutic HPV vaccine for cervical cancer.
Many patients have since been treated, and based on early promising research,
phase II trials are scheduled to begin in winter 2009.